Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of IV difelikefalin 0.5 mcg/kg for pruritus
2018-001930-17Phase 3Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Aug 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pruritus comparing IV difelikefalin 0.5 mcg/kg with Placebo (2 arms). Primary endpoint: Primary Efficacy Endpoint. Started Aug 2018; status: completed.
02
Drugs
difelikefalin
03
Conditions
pruritus
Beyond the preview
Go deeper on 2018-001930-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001930-17.